Compare Illumina, Inc. (ILMN) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nu Holdings Ltd — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Nu Holdings Ltd trades at $13.64 (market cap $66.85B). The key difference: Nu Holdings Ltd is far larger — about 2.3× Illumina, Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| ILMN | NU | |
|---|---|---|
Market Cap | $28.96B | $66.85B |
Sector | Health | Financials |
52-Week High | $205.10 | $18.76 |
52-Week Low | $91.00 | $11.60 |
Enterprise Value | $30.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Nu Holdings (NU) trades at $13.84, down 1.98% with a bearish technical outlook. The company shows strong fundamental growth with revenue increasing from $3.0B in 2022 to $10.6B in 2025 and net income turning positive to $2.9B. Recent earnings show mixed results with two misses but a beat in Q3 2025. Analyst consensus remains bullish with a $14.98 price target despite recent price weakness.
Nu presents a compelling growth story with expanding profitability and market position in Latin American banking. Key risks include unsecured credit exposure and regional economic volatility. The current valuation at 21.35 P/E offers potential upside if the company maintains its growth trajectory and executes on expansion plans in Brazil and Mexico.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
